Trials / Unknown
UnknownNCT05862831
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic and Primary Efficacy of PM1003 in Patients With Advanced Solid Tumors and Phase IIa Study to Evaluate the Primary Efficacy of PM1003 in Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 285 (estimated)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-lable, multicenter phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PM1003 in the treatment of advanced solid tumors.
Detailed description
PM1003 is a Bispecific Antibody Targeting PD-L1 and 4-1BB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PM1003 Injection | Subjects will receive PM1003 by intravenous administration. |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2025-09-07
- Completion
- 2025-11-15
- First posted
- 2023-05-17
- Last updated
- 2023-05-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05862831. Inclusion in this directory is not an endorsement.